# q01 rev 1 - local removal probe without D05 (platform Doc 6), 2026-10-06

Design evidence, not a blind solve. Fresh blind-solver on packet runs/q01-r1-probe-t3/solver-1:
a byte copy of the rev 1 solver-1 packet minus D05, remaining ids renumbered contiguously
(probe D05 = D06), neutral run name, bound with docket_agent.bind_scope. Prompt: root, packet,
verbatim rev 1 question, plus a forced best answer with probability.

Raw return as received (probe ids):

**answer:** The packet doesn't settle this. My forced best answer is **"High-single digit growth"**: that is the FY2026 adjusted operating income guidance for "Other" in the May 6, 2026 release. I put the probability that it is correct at about 0.5.

**confidence:** low

**path:**
1. **The group is "Other".** D05:121 (Nov 5, 2025): "Other, which is not considered a reportable segment, will consist of businesses for which the Company has begun to explore strategic alternatives and includes MWI Animal Health, Profarma, U.S. Consulting Services and the other components of PharmaLex." D01:81 and D03:86 say the same: "other businesses … have been grouped together in Other. These businesses include … U.S. Consulting Services…"
2. **The three guidance snapshots for Other's adjusted operating income** (all against an FY2025 base of $352M):
   - D05:138 (Nov 5, 2025): "Other(1)|1% to 4% decline|$352M"
   - D01:114 (Feb 4, 2026): "Other(2)|Flat|$352M"
   - D03:123 (May 6, 2026): "Other(2)|High-single digit growth|$352M"
3. **Status on Feb 4, 2026: held for sale, not sold.** D01:47 refers to "a $249.5 million impairment of assets related to its U.S. Consulting Services business that is classified as held for sale". D01:103 says guidance reflects "improved results in Other as certain depreciable assets have been fully impaired as of December 31, 2025". That implies the business was expected to stay in Other. The only completion listed in D01 is OneOncology (D01:99).
4. **Status on May 6, 2026: no sign the sale had closed.**
   - D03:86 still says the company "is exploring strategic alternatives" for a list that includes U.S. Consulting Services.
   - D03:102 blames the Q2 decline on operations ("a decrease in sales at our consulting services businesses"), not on a sale.
   - The highlights (D03:106–108) cover only the MWI–Covetrus merger and the EyeSouth deal.
   - The guidance rationale (D03:112) mentions only "MWI now being accounted for as 'held for sale'".
   - FY2026 has no gain or loss on divestiture, and the cash flow statement has no divestiture-proceeds line (D03:617–622).
5. **Inference, not a stated fact.** The sale most likely closed after May 6, 2026. If it closed before the next quarterly update (early August 2026), the guidance in force was the May 6 figure: "High-single digit growth".

The completion date itself doesn't appear anywhere in the packet. I searched every text file for complet, sold, sale of, divest, transaction, proceeds, closing and exit. The only hits were OneOncology, EyeSouth, conference-call replays and FY2025 non-core divestitures (for example D05:282 and D04:249).

**minimal_documents:** D03 alone gives the group membership, the forced-answer guidance and the evidence that the sale hadn't closed. D01 is needed to rule out a closing before Feb 4 and to supply the alternative answer. D05 supplies the November guidance. No document in the packet states the completion date.

**readings:**
- **Closed between Feb 4 and May 6, 2026:** the answer would be **"Flat"** (D01:114). I'd put this at about 0.25. The only support is that D03 renamed a line item to "Acquisition and divestiture-related deal and integration expenses" (D03:192). That could just as well be MWI deal costs.
- **Closed before Feb 4, 2026:** the answer would be **"1% to 4% decline"** (D05:138). This is unlikely given D01's "is classified as held for sale" wording.
- **Closed after the Q3 FY2026 update (around August 2026):** the guidance in force would be a figure that isn't in the packet.
- **Reading "completed" loosely as the held-for-sale classification or impairment in Q1 FY2026:** the answer would be "1% to 4% decline" or "Flat", depending on the reference date.

**gaps:**
- The completion date, and the fact that the divestiture was completed at all, is missing from the packet.
- No Q3 FY2026 release or later 8-K is included.
- Coverage:
  - Fully read: D01 and D03.
  - Partly read: D05 (lines 1–180 and the footnote at line 415); the rest was covered by searches.
  - Searched only: D02 and D04 (FY2025 releases, with partial reads of D04).
- docs/ holds only .txt sources with no PDFs, so there was no original page to inspect. The guidance tables extracted cleanly. Bolding that marks updated metrics was lost, which doesn't affect the answer.

**contaminated:** no

Files:
- D:\Dev\Docket\tasks\aq-01322\runs\q01-r1-probe-t3\solver-1\text\D03.txt
- D:\Dev\Docket\tasks\aq-01322\runs\q01-r1-probe-t3\solver-1\text\D01.txt
- D:\Dev\Docket\tasks\aq-01322\runs\q01-r1-probe-t3\solver-1\text\D05.txt

Caller note: forced best answer "High-single digit growth" (p 0.5), not the gold; Flat only as a
0.25 alternative. Rev 0's same probe had Flat as the best answer (p 0.5). The rewording moved
the no-Doc-6 answer away from the gold.
